Literature DB >> 24277784

Pre-existing cross-reactive antibodies to avian influenza H5N1 and 2009 pandemic H1N1 in US military personnel.

Sathit Pichyangkul1, Somporn Krasaesub, Anan Jongkaewwattana, Arunee Thitithanyanont, Suwimon Wiboon-Ut, Kosol Yongvanitchit, Amporn Limsalakpetch, Utaiwan Kum-Arb, Duangrat Mongkolsirichaikul, Nuanpan Khemnu, Rangsini Mahanonda, Jean-Michel Garcia, Carl J Mason, Douglas S Walsh, David L Saunders.   

Abstract

We studied cross-reactive antibodies against avian influenza H5N1 and 2009 pandemic (p) H1N1 in 200 serum samples from US military personnel collected before the H1N1 pandemic. Assays used to measure antibodies against viral proteins involved in protection included a hemagglutination inhibition (HI) assay and a neuraminidase inhibition (NI) assay. Viral neutralization by antibodies against avian influenza H5N1 and 2009 pH1N1 was assessed by influenza (H5) pseudotyped lentiviral particle-based and H1N1 microneutralization assays. Some US military personnel had cross-neutralizing antibodies against H5N1 (14%) and 2009 pH1N1 (16.5%). The odds of having cross-neutralizing antibodies against 2009 pH1N1 were 4.4 times higher in subjects receiving more than five inactivated whole influenza virus vaccinations than those subjects with no record of vaccination. Although unclear if the result of prior vaccination or disease exposure, these pre-existing antibodies may prevent or reduce disease severity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24277784      PMCID: PMC3886412          DOI: 10.4269/ajtmh.13-0151

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

Review 1.  The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance.

Authors:  Mark V Rubertone; John F Brundage
Journal:  Am J Public Health       Date:  2002-12       Impact factor: 9.308

2.  Cross-reactive H1N1 antibody responses to a live attenuated influenza vaccine in children: implication for selection of vaccine strains.

Authors:  Min-Shi Lee; Chin-Fen Yang
Journal:  J Infect Dis       Date:  2003-10-16       Impact factor: 5.226

3.  Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain.

Authors:  Paul M Mendelman; Ruth Rappaport; Iksung Cho; Stan Block; William Gruber; Marilyn August; Denise Dawson; Julie Cordova; George Kemble; Kutubuddin Mahmood; Giuseppe Palladino; Min-Shi Lee; Ahmad Razmpour; Jeffrey Stoddard; Bruce D Forrest
Journal:  Pediatr Infect Dis J       Date:  2004-11       Impact factor: 2.129

Review 4.  Immunization to protect the US Armed Forces: heritage, current practice, and prospects.

Authors:  John D Grabenstein; Phillip R Pittman; John T Greenwood; Renata J M Engler
Journal:  Epidemiol Rev       Date:  2006-06-08       Impact factor: 6.222

5.  Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates.

Authors:  C R Lambré; H Terzidis; A Greffard; R G Webster
Journal:  J Immunol Methods       Date:  1990-12-31       Impact factor: 2.303

6.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

7.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Authors:  Kathy Hancock; Vic Veguilla; Xiuhua Lu; Weimin Zhong; Eboneé N Butler; Hong Sun; Feng Liu; Libo Dong; Joshua R DeVos; Paul M Gargiullo; T Lynnette Brammer; Nancy J Cox; Terrence M Tumpey; Jacqueline M Katz
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

8.  Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

Authors:  Matthew R Sandbulte; Gretchen S Jimenez; Adrianus C M Boon; Larry R Smith; John J Treanor; Richard J Webby
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

9.  Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China.

Authors:  Honglin Chen; Yong Wang; Wei Liu; Jinxia Zhang; Baiqing Dong; Xiaohui Fan; Menno D de Jong; Jeremy Farrar; Steven Riley; Gavin J D Smith; Yi Guan
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

Review 10.  Avian influenza A (H5N1) age distribution in humans.

Authors:  Matthew Smallman-Raynor; Andrew D Cliff
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more
  5 in total

1.  Absence of neutralizing antibodies against influenza A/H5N1 virus among children in Kamphaeng Phet, Thailand.

Authors:  Benjawan Khuntirat; Christopher S Love; Darunee Buddhari; Gary L Heil; Robert V Gibbons; Alan L Rothman; Anon Srikiatkhachorn; Gregory C Gray; In-Kyu Yoon
Journal:  J Clin Virol       Date:  2015-06-03       Impact factor: 3.168

2.  H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.

Authors:  Aditya Ambati; Davide Valentini; Emanuele Montomoli; Guilia Lapini; Fabrizio Biuso; Holger Wenschuh; Isabelle Magalhaes; Markus Maeurer
Journal:  Immunology       Date:  2015-04-15       Impact factor: 7.397

3.  Cross-immunity and age patterns of influenza A(H5N1) infection.

Authors:  A J Kucharski; W J Edmunds
Journal:  Epidemiol Infect       Date:  2014-08-13       Impact factor: 2.451

4.  Factors associated with clinical outcome in 25 patients with avian influenza A (H7N9) infection in Guangzhou, China.

Authors:  Hui Wang; XinCai Xiao; Jianyun Lu; Zongqiu Chen; Kuibiao Li; Hui Liu; Lei Luo; Ming Wang; ZhiCong Yang
Journal:  BMC Infect Dis       Date:  2016-10-03       Impact factor: 3.090

5.  Different Repeat Annual Influenza Vaccinations Improve the Antibody Response to Drifted Influenza Strains.

Authors:  Ewan P Plant; Lucy J Fredell; Blake A Hatcher; Xing Li; Meng-Jung Chiang; Martina Kosikova; Hang Xie; Olga Zoueva; Angelia A Cost; Zhiping Ye; Michael J Cooper
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.